| 查看: 119 | 回复: 0 | |||
| 当前主题已经存档。 | |||
abcd888898银虫 (正式写手)
|
[交流]
【转帖】XOMA Reviews Priorities for 2010 and 2009 Accomplishments
|
||
|
XOMA Reviews Priorities for 2010 and 2009 Accomplishments BERKELEY, Calif., Jan 19, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today provided a summary of its priorities for 2010 and accomplishments during 2009. "In 2009, we continued to advance our lead product candidate, XOMA 052, an antibody to interleukin-1 beta (IL-1 beta), into Phase 2 development as a potentially paradigm-shifting anti-inflammatory approach to the treatment of Type 2 diabetes and cardio-metabolic diseases," said Steven B. Engle, XOMA's Chairman and Chief Executive Officer. "Most significantly, we expanded the XOMA 052 program beyond our focus on diabetes to cardiovascular disease. This expansion was supported by results from our Phase 1 trials demonstrating benefit in biomarkers of cardiovascular disease, animal studies evaluating XOMA 052 in cardio-metabolic disease models, and studies with other IL-1 targeting agents that have shown the potential for cardiovascular benefit from IL-1 inhibition, some results of which are expected to be presented at the American College of Cardiology meeting in March." |
回复此楼» 猜你喜欢
中山大学-第七医院-招科研助理1名（基因设计和克隆、RNA合成）
已经有1人回复
-
巴黎萨克雷大学与国家留学基金委合作博士研究生项目-脂质纳米药物/生物材料/多酚递送
已经有10人回复
-
药理学论文润色/翻译怎么收费?
已经有136人回复
-
己酮可可碱过氧化杂质限度
已经有2人回复
-
求助Isoeugenol质量标准
已经有0人回复
-
Gliclazide
已经有0人回复
-
塞替派/噻替哌（Thiotepa） 质量控制
已经有16人回复
-
有没有大佬可以帮忙查下Trijardy XR和Qternmet XR历年销售数据呀
已经有0人回复
-
酰胺水解求助
已经有11人回复
-
中药材标准目录大全llp2026（含各省市中药材和炮制规范）
已经有0人回复